Clinical trials: Cancer, Head
Renal Cancer, Renal Clear Cell Carcinoma
CD70-targeted immunoPET Imaging of Malignant Cancers
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma…
- Conditions
- Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT06852638
- Testing
- [18F]F-RESCA-RCCB6, [18F]F-RESCA-R8B4, [68Ga]Ga-NOTA-R8B4
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital
Head and Neck Neoplasms
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin or cetuximab) and radiation therapy in participants with locally advanced head and neck cancer.
- Trial name
- NCT02555644
- Testing
- Prexasertib, Cisplatin, Cetuximab
- Where
- 4 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Leukemia
Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00019409
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 6 sites in United States, India
- Sponsor
- National Institutes of Health Clinical Center (CC)
Head and Neck Cancer, Oral Complications
Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
RATIONALE: Sargramostim may lessen symptoms of mucositis in patients receiving radiation therapy for head and neck cancer. It is not yet known if sargramostim is more effective than no treatment in reducing mucositis caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00008398
- Testing
- sargramostim, quality-of-life assessment, radiation therapy
- Where
- 236 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Neoplasms
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage…
- Trial name
- BelieveIT-201 (NCT05980598)
- Testing
- TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 β/γ
- Where
- 65 sites in United States, Georgia and 6 more
- Volunteers
- 27 people
- Sponsor
- Ascendis Pharma A/S
Maximum Interincisal Opening
Effects of Exercise Therapy Adjuvant Device on Head and Neck Cancer Patients in the Treatment of Cancer Therapy Induced Trismus
Trismus is traditionally considered being a late effect of cancer therapy with functional deficits becoming clear in the first year after completing radiation therapy.
- Trial name
- NCT04740216
- Testing
- exercise therapy plus jaw device, exercise therapy
- Volunteers
- 130 people
- Sponsor
- Taipei Medical University
Esophageal Cancer, Esophagus Cancer
Retrospective Review of Esophageal Cancer at MSKCC
Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin…
- Trial name
- NCT05706558
- Testing
- Esophagectomy
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hyperparathyroidism, Primary, Parathyroid Neoplasms
WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making
Primary hyperparathyroidism is usually cured by removing the single over-active parathyroid adenoma. During surgery, however, surgeons often see a thin rim of normal parathyroid tissue that still "glows" under a near-infrared…
- Conditions
- Hyperparathyroidism, Primary, Parathyroid Neoplasms, Parathyroid Adenoma, Hypocalcemia
- Trial name
- WHITE CAP-PTS (NCT07043010)
- Testing
- Near-Infrared Parathyroid Tissue Sensor Imaging (PTS), Rim-Preservation Technique, En-bloc Resection Technique
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Medical University
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Nasopharyngeal Carcinoma
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication…
- Trial name
- NCT06239727
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin (80 mg/m2)
- Where
- 26 sites in China
- Volunteers
- 593 people
- Sponsor
- Sun Yat-sen University
Cancer, Oropharynx, Pain, Intractable
Ropivacaine/Dexamethasone and 10% Lignocaine Injection in GPN Block for Intractable Cancer Pain
The study will compare the efficacy and safety of Ropivacaine/dexamethasone vs 10% lignocaine injection in distal glossopharyngeal nerve block for intractable cancer pain
- Conditions
- Cancer, Oropharynx, Pain, Intractable, Cancer Pain
- Trial name
- NCT04085120
- Testing
- 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection, 10% lignocaine injection
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences
Head and Neck Cancer
Efficacy of ONS Supplementation in HNC Outpatient Under Treatment
A RCT study to compare the efficacy of ONS supplementation with standard dietary advice on nutritional outcome inHNC outpatients undergoing treatment in radiotherapy clinic.
- Trial name
- NCT03688646
- Testing
- Intensive Nutrition Intervention
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute, Malaysia
Thyroid Cancer
Identification of Molecular Biomarkers for Thyroid Cancer
This is a two part study; part A proposes to collect plasma samples to examine how ctDNA (circulating thyroid DNA) markers correlate with detection of recurrent disease, response to therapy, clinical outcome and pathological…
- Trial name
- NCT04133870
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Head and Neck Cancer
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00281840
- Testing
- bevacizumab, docetaxel, conventional surgery
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Trial name
- NCT05904080
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 92 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
This study will estimate overall response rate of pemetrexed in poor risk patients with advanced, metastatic, or recurrent squamous cell carcinoma of the head and neck.
- Trial name
- NCT00293579
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Carcinoma, Squamous Cell of Head and Neck
Treatment of Advanced Head and Neck Cancer
This study will investigate the efficacy of opioid growth factor (OGF) on tumor size and survival in patients with head and neck cancer who have failed standard therapy.
- Trial name
- NCT00982696
- Testing
- Opioid Growth Factor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Milton S. Hershey Medical Center
Esophageal Neoplasm, Rectal Neoplasms
Prospective Study Evaluating the Feasibility of Fiducial Markers Placement for Patients With Esophageal or Rectal Cancer
It is a multicenter prospective observational study including consecutive patients with esophageal tumor or rectum with indication for radiotherapy The main objective of this study is to evaluate the feasibility of fiducial…
- Trial name
- FIDECHO (NCT03057288)
- Testing
- fiducial markers placement
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Société Française d'Endoscopie Digestive
Esophageal Cancer
QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer
China bears a disproportionately high burden of esophageal cancer, accounting for approximately 50% of newly diagnosed cases worldwide, with an average 5-year survival rate of only 30%.
- Trial name
- BRICES (NCT07283991)
- Testing
- chemotherapy combined with Aparolitolovureli immunotherapy
- Volunteers
- 24 people
- Sponsor
- Ruijin Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.